{
    "2019-08-16": [
        [
            {
                "time": "2018-04-17",
                "original_text": "A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis",
                "features": {
                    "keywords": [
                        "FDA",
                        "Novartis",
                        "AveXis",
                        "Breach",
                        "Trust"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-05-01",
                "original_text": "AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Calquence",
                        "FDA",
                        "Breakthrough",
                        "CLL"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis",
                "features": {
                    "keywords": [
                        "FDA",
                        "Novartis",
                        "AveXis",
                        "Breach",
                        "Trust"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-06-12",
                "original_text": "Gene therapies to test FDA's approach to regulating drugs after launch, experts say",
                "features": {
                    "keywords": [
                        "Gene",
                        "therapies",
                        "FDA",
                        "regulating",
                        "drugs",
                        "launch",
                        "experts"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}